Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1796-1801

  Uchida, N ^a   Takeda, Y ^a   Hojo, K ^a   Maekawa, R ^a   Sugita, K ^a   Yoshioka, T ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

5 FU; Cisplatin; Combination chemotherapy; Nedaplatin; Platinum complex

Indexed keywords

CISPLATIN; FLUOROURACIL; NEDAPLATIN; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEWIS CARCINOMA; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LEWIS LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS;

EID: 0032190379     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00194-4     Document Type: Article

References (29)

1. 1. Totani T, Aono K, Komura M, Adachi Y. Synthesis of (glycolato-O, O′) diammineplatinum (II) and its related complexes. Chem Lett 1986, 3, 429-432.
2. 2. Suzumura S, Kato T, Ueda R, Ohta K. Effect of treatment schedule on antitumor activity of glycolato-O, O′-diammine-platinum (II), a new platinum derivative: comparison with cis-diamminedichloroplatinum (II). Anticancer Res 1989, 9, 1083-1088.
3. 3. Shiratori O, Kasai H, Uchida N, Takeda Y, Totani T, Sato K. Anti-tumor activity of 254-S, a platinum complex, in rodents. In Ishigami J, ed. Recent Advances in Chemotherapy. Tokyo, University of Tokyo Press, 1985, 635-636.
4. 4. Koenuma M, Kasai H, Uchida N, et al. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammine glycolatoplatinum (254-S) and cis-diammine dichloroplatinum. Anticancer Res 1995, 15, 417-422.
5. 5. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990, 52, 15-24.
6. 6. Furuse K, Fukuoka M, Ohshima S, et al. Phase II clinical study of (glycolato-O, O′) diammineplatinum (II), a new platinum complex, for primary lung cancer. Proc Am Soc Clin Oncol 1989, 8, 238.
7. 7. Fukuda M, Shinkai T, Eguchi K, et al. Phase II study of (glycolato-O, O′) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990, 26, 393-396.
8. 8. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ohta K. An early phase II study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 1992, 19, 863-869.
9. 9. Akaza H, Togashi M, Nishio Y, et al. Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992, 31, 187-192.
10. 10. Kato T, Noda K, Hirabayashi K, Nishimura H. Phase II study of cis-diammine (glycolato) platinum [254-S], a new platinum complex, for gynecological malignancy. Proc 16th Int Cong Chemother, Anticancer Section 1989, 823, 1-2.
11. 11. Pratesi G, Gianni L, Manzotti C, Zuninno F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloro-platinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988, 21, 237-240.
12. 12. Shirasaka T, Shimamoto Y, Ohshima H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993, 32, 167-172.
13. 13. Keane TE, Gingrich JR, Rosner G, Webb KS, Poulton SH, Walther PJ. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res 1994, 54, 475-481.
14. 14. Loehrer PJ, Einhorn LH, Williams SD, Huli SL, Estes NC, Pennington K. Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. Cancer Treat Rep 1985, 69, 1359-1363.
15. 15. Decker DA, Drelichman A, Jacobs J. Adjuvant chemotherapy with cis-diamminedichloroplatinum 11 and 120-hour-infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of head and neck. Cancer 1986, 51, 1353-1355.
16. 16. Ohtsu A, Yoshida S, Saito D, et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991, 21, 120-124.
17. 17. Uchida N, Kasai H, Takeda Y, Maekawa R, Sugita K, Yoshioka T. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma. Anticancer Res 1998 18, 247-252.
18. 18. Ekimoto H, Aikawa M, Takahashi K, Mastuda A. Fundamental studies on combination chemotherapy of cisplatin with peplomycin against human squamous cell carcinomas in nude mice. Jpn J Cancer Chemother 1985, 12, 70-76.
19. 19. Berenbaum MC. Criteria for analysing interactions between biologically active agents. Adv in Cancer Res 1981, 35, 269-335.
20. 20. Koenuma M, Kasai H, Uchida N, et al. Antitumor activity of a new platinum complex, nedaplatin. Clin Rep 1995, 29, 259-268.
21. 21. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980, 47, 1-9.
22. 22. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964, 20, 482-491.
23. 23. Diaz-Rubio E, Milla A, Jimero J, et al. Lack of clinical synergism between cisplatin (CDDP) and 5-fluorouracil (5-FU) in advanced colorectal cancer (CRC). Results of a randomized study. Proc Am Soc Clin Oncol 1988, 7, 110.
24. 24. Kemeny N, Israel K, Niedzwiecki D, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin patients with metastatic colorectal cancer. J Clin Oncol 1990, 8, 313-318.
25. 25. Ozawa S, Sugiyama Y, Mitsuhasi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 1988, 21, 185-190.
26. 26. Sasaki Y, Tamura T, Eguchi K, et al. Pharmacokinetics of (glycolato-O.O′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989, 23, 243-246.
27. 27. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical bases for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986, 83, 8923-8925.
28. 28. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996, 65, 479-484.
29. 29. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diammine-dichloro-platinum metabolism and ATP-dependent efflux from leukemia cell. J Biol Chem 1993, 268, 20116-20125.